Method for enhancing folding and transport of misfolded glucocerebrosidase
Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
1. A method of enhancing transport of misfolded GCase to a lysosome in a patient suffering from Parkinson's Disease, consisting of administering to the patient a pharmaceutically acceptable amount of ambroxol, ambroxol hydrochloride, or bromhexine or a pharmaceutically acceptable salt thereof, wherein said ambroxol, ambroxol hydrochloride or bromhexine or a pharmaceutically acceptable salt thereof enhances transport of the misfolded GCase to the lysosome.
2. The method of claim 1 , consisting of administering ambroxol or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein said patient has Gaucher's Disease.
4. The method of claim 2 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
5. The method of claim 1 , consisting of administering bromhexine or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein said patient has Gaucher's Disease.
7. The method of claim 5 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
8. A method of enhancing proper folding of misfolded GCase in a patient suffering from Parkinson's Disease, consisting of administering to the patient a pharmaceutically acceptable amount of ambroxol, ambroxol hydrochloride, or bromhexine or a pharmaceutically acceptable salt thereof, wherein said ambroxol, ambroxol hydrochloride, or bromhexine or a pharmaceutically acceptable salt thereof enhances proper folding of the misfolded GCase.
9. The method of claim consisting of administering ambroxol hydrochloride.
10. The method of claim 9 , wherein said patient has Gaucher's Disease.
11. The method of claim 9 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
12. The method of claim 11 , wherein the mutation in the gene encoding a beta glucocerebrosidase is selected from:
a. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
b. Point mutations at L444P, A456P, and V460V;
c. Point mutations at D140H and E326K;
d. Point mutations at H255Q and D409H;
e. Guanine insertion at 84GG;
f. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
g. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
h. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
i. A homozygous 259C-T transition (1763 in the genomic DNA)
j. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
k. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
13. The method of claim 12 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
14. The method of claim 12 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.
15. The method of claim 4 , wherein the patient has mutation in the gene encoding a beta glucocerebrosidase selected from:
a. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
b. Point mutations at L444P, A456P, and V460V;
c. Point mutations at D140H and E326K;
d. Point mutations at H255Q and D409H;
e. Guanine insertion at 84GG;
f. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
g. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
h. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
i. A homozygous 259C-T transition (1763 in the genomic DNA)
j. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
k. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
16. The method of claim 15 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
17. The method of claim 15 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.
18. The method of claim 7 , wherein the patient has mutation in the gene encoding a beta glucocerebrosidase selected from:
a. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
b. Point mutations at L444P, A456P, and V460V;
c. Point mutations at D140H and E326K;
d. Point mutations at H255Q and D409H;
e. Guanine insertion at 84GG;
f. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
g. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
h. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
i. A homozygous 259C-T transition (1763 in the genomic DNA)
j. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
k. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
19. The method of claim 18 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
20. The method of claim 18 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.
21. The method of claim 8 , consisting of administering ambroxol or a pharmaceutically acceptable salt thereof.
22. The method of claim 21 , wherein said patient has Gaucher's Disease.
23. The method of claim 21 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
24. The method of claim 23 , wherein the mutation in the gene encoding a beta glucocerebrosidase is selected from:
a. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
b. Point mutations at L444P, A456P, and V460V;
c. Point mutations at D140H and E326K;
d. Point mutations at H255Q and D409H;
e. Guanine insertion at 84GG;
f. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
g. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
h. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
i. A homozygous 259C-T transition (1763 in the genomic DNA)
j. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
k. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
25. The method of claim 24 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
26. The method of claim 24 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.
27. The method of claim 8 , consisting of administering bromhexine or a pharmaceutically acceptable salt thereof.
28. The method of claim 27 , wherein said patient has Gaucher's Disease.
29. The method of claim 27 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
30. The method of claim 29 , wherein the mutation in the gene encoding a beta glucocerebrosidase is selected from:
l. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
m. Point mutations at L444P, A456P, and V460V;
n. Point mutations at D140H and E326K;
o. Point mutations at H255Q and D409H;
p. Guanine insertion at 84GG;
q. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
r. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
s. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
t. A homozygous 259C-T transition (1763 in the genomic DNA)
u. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
v. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
31. The method of claim 30 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
32. The method of claim 30 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.
33. The method of claim 8 , consisting of administering ambroxol hydrochloride.
34. The method of claim 33 , wherein said patient has Gaucher's Disease.
35. The method of claim 33 , wherein said patient has a mutation in the gene encoding a beta glucocerebrosidase.
36. The method of claim 35 , wherein the patient has mutation in the gene encoding a beta glucocerebrosidase selected from:
l. A point mutation comprising V15L, G46E, K79N, R119Q, P122S, R131L, K157Q, N188S, Y212H, F213I, F216V, F216Y, F251L, R257E, P289L, A309V, H311R, W312C, Y323I, G325R, C342G, R353G, R359X (termination), S364T, N370S, L371V, G377S, V394L, V398F, P401L, D409H, D409V, P415R, L444P, R463C, G478S, or R496H;
m. Point mutations at L444P, A456P, and V460V;
n. Point mutations at D140H and E326K;
o. Point mutations at H255Q and D409H;
p. Guanine insertion at 84GG;
q. Splice site mutation in intron 2 (IVS2DS+1G-A), resulting in the skipping of exon 2;
r. A 1-bp deletion (1023delC in the genomic sequence) in the GCase gene,
s. A 55-bp deletion (nucleotides 5879-5933 in genomic DNA) in the GCase gene;
t. A homozygous 259C-T transition (1763 in the genomic DNA)
u. A homozygous 1-bp deletion in the GCase gene, resulting in a frameshift and premature truncation of the protein in exon 6; and
v. A G-to-A substitution at the first position in the splice site of intron 10 of the GCase gene, resulting in the insertion of the first 11 base pairs of IVS10 and deletion of the first 11 base pairs of exon 11.
37. The method of claim 36 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises N370S.
38. The method of claim 36 , wherein the mutation in the gene encoding a beta-glucocerebrosidase comprises L444P.